Sun Pharma to offer lower drug prices in the United States
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below: Sun Pharmaceutical Industries, an Indian drugmaker, has agreed to apply a Most Favoured Nation pricing model to its future innovative launches in the United States, aiming to keep medicines affordable for American patients. The company will also invest in a new manufacturing plant in the U.S. and has signed a deal with the U.S. government to extend affordable medicines to Medicaid programs. The agreement comes amid a delay of Section 232 tariffs, giving the company more time to implement the pricing strategy.
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Amid increased tariffs, Sun Pharma to invest, set up plant in US, signs deal
Timeline
First reported by Economic Times on ; 2 articles from 2 outlets so far.
Who is covering this story
- Center (2): Economic Times, DNA India